Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Probe Drug Cocktail · 1 trial · 1 indication
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module. Adverse events for this outcome measure are reported by arm. SAEs are reported by study drug in the Adverse Events module.
| Arm | Type | Description |
|---|---|---|
| Probe Drug Cocktail (Cohort 1a) | EXPERIMENTAL | Probe Drug Cocktail administered orally on Day -3. |
| 200 milligrams (mg) Lasmiditan+Probe Drug Cocktail (Cohort 1) | EXPERIMENTAL | 200 mg lasmiditan administered alone, orally, on Days 1-6 and concurrently with probe drug cocktail on Day 7. |
| Placebo+Probe Drug Cocktail (Cohort 1b) | PLACEBO_COMPARATOR | Placebo administered alone, orally, on Days 1-6 and concurrently with probe drug cocktail on Day 7. |
| 400 mg Lasmiditan (Cohort 2a) | EXPERIMENTAL | 400 mg lasmiditan administered orally for 7 days. |
| Placebo (Cohort 2b) | EXPERIMENTAL | Placebo administered orally for 7 days. |
| Name | Type | Description |
|---|---|---|
| Probe Drug Cocktail | DRUG | Administered orally |
| Lasmiditan | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Healthy males or females, as determined by medical history and physical examination * Have a body mass index (BMI) of 19.0 to 35.0 kilograms per meter squared (kg/m²) inclusive, at the time of screening Exclusion Criteria: * Have participated, within the last 30 days, in a c...
Probe Drug Cocktail is an investigational small molecule being studied in healthy participants. It is currently in Phase 1 clinical development, with a completed trial involving 70 participants in the United States. The drug is being evaluated for use in healthy individuals as part of early-stage research.
Probe Drug Cocktail is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting Phase 1 clinical trials to evaluate the drug in healthy participants.
Probe Drug Cocktail is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials. One Phase 1 study has been completed, involving 70 healthy participants in the United States.
Probe Drug Cocktail has one completed clinical trial, registered as NCT03252015, titled "A Study of Multiple Doses of Lasmiditan in Healthy Participants." This Phase 1 study enrolled 70 healthy participants in the United States and was a randomized, double-blind, placebo-controlled trial.
Probe Drug Cocktail is associated with the drug lasmiditan, as indicated by the clinical trial title NCT03252015, which studied multiple doses of lasmiditan in healthy participants. The trial was conducted by Eli Lilly and Company, the developer of Probe Drug Cocktail.